1. Home
  2. KURA

KURA

Kura Oncology Inc.

Logo Kura Oncology Inc.

Health Care

Biotechnology: Biological Products (No Diagnostic Substances)

Nasdaq

as 04-12-2024 4:00pm EST

$
-
-
.
-
-
-
$
-
.
-
-
-
-
.
-
-
%

Kura Oncology Inc is a clinical-stage biopharmaceutical company, that engages in discovering and developing therapeutics for the treatment of solid tumors and blood cancers. It focuses on the development of small-molecule product candidates that target cell signaling pathways to drive the progression of various cancers. The company has a product candidate, Tipifarnib, which is a farnesyl transferase inhibitor, in both solid tumors and blood cancers. Geographically operation of the group is carried through the United States.

Founded: 2014 Country:
United States
United States
Employees: N/A City: SAN DIEGO
Market Cap: 1.6B IPO Year: N/A
Target Price: $28.05 AVG Volume (30 days): 1.4M
Analyst Decision: Strong Buy Number of Analysts: 10
Dividend Yield: N/A Dividend Payout Frequency: N/A
EPS: -2.08 EPS Growth: N/A
52 Week Low/High: $7.41 - $24.17 Next Earning Date: 05-08-2024
Revenue: N/A Revenue Growth: N/A
Revenue Growth (this year): N/A Revenue Growth (next year): N/A

Share on Social Networks: